IL176594A0 - Modified human four helical bundle polypeptides and their uses - Google Patents

Modified human four helical bundle polypeptides and their uses

Info

Publication number
IL176594A0
IL176594A0 IL176594A IL17659406A IL176594A0 IL 176594 A0 IL176594 A0 IL 176594A0 IL 176594 A IL176594 A IL 176594A IL 17659406 A IL17659406 A IL 17659406A IL 176594 A0 IL176594 A0 IL 176594A0
Authority
IL
Israel
Prior art keywords
modified human
helical bundle
bundle polypeptides
polypeptides
helical
Prior art date
Application number
IL176594A
Other languages
English (en)
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of IL176594A0 publication Critical patent/IL176594A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
IL176594A 2004-02-02 2006-06-28 Modified human four helical bundle polypeptides and their uses IL176594A0 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US54152804P 2004-02-02 2004-02-02
US58131404P 2004-06-18 2004-06-18
US58088504P 2004-06-18 2004-06-18
US58117504P 2004-06-18 2004-06-18
US63861604P 2004-12-22 2004-12-22
PCT/US2005/003537 WO2005074650A2 (en) 2004-02-02 2005-01-28 Modified human four helical bundle polypeptides and their uses

Publications (1)

Publication Number Publication Date
IL176594A0 true IL176594A0 (en) 2008-04-13

Family

ID=34842043

Family Applications (3)

Application Number Title Priority Date Filing Date
IL176594A IL176594A0 (en) 2004-02-02 2006-06-28 Modified human four helical bundle polypeptides and their uses
IL176596A IL176596A0 (en) 2004-02-02 2006-06-28 Modified human interferon polypeptides and their uses
IL176595A IL176595A (en) 2004-02-02 2006-06-28 Different human growth hormone polypeptides and their uses

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL176596A IL176596A0 (en) 2004-02-02 2006-06-28 Modified human interferon polypeptides and their uses
IL176595A IL176595A (en) 2004-02-02 2006-06-28 Different human growth hormone polypeptides and their uses

Country Status (15)

Country Link
US (15) US8119603B2 (enExample)
EP (4) EP2327724A3 (enExample)
JP (3) JP4896745B2 (enExample)
KR (3) KR20060130182A (enExample)
CN (1) CN103755800B (enExample)
AT (1) ATE546463T1 (enExample)
AU (5) AU2005211362B2 (enExample)
BR (3) BRPI0507169A (enExample)
CA (3) CA2553035A1 (enExample)
GB (3) GB2429207A (enExample)
IL (3) IL176594A0 (enExample)
MX (3) MXPA06008507A (enExample)
NZ (4) NZ548255A (enExample)
SG (1) SG135176A1 (enExample)
WO (3) WO2005074546A2 (enExample)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
EP1584680A1 (en) * 2004-04-08 2005-10-12 Boehringer Ingelheim Austria GmbH Fed-batch fermentation process for the production of plasmid DNA
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
JP2008507280A (ja) * 2004-07-21 2008-03-13 ケンブレツクă‚čăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒ„ăƒ‰ éžć€©ç„¶ă‚łăƒŒăƒ‰ă‚ąăƒŸăƒŽé…žă‚’ç”šă„ăŸç”ŸćˆæˆăƒăƒȘペプチド
EP1805217A2 (en) * 2004-10-18 2007-07-11 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
MX2007007587A (es) * 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
WO2006073846A2 (en) * 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
KR20070090023A (ko) * 2004-12-22 2007-09-04 ì•”ëžŒëŁ©ìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ 변형 읞간 성임 혞넎ëȘŹ
ZA200704926B (en) * 2004-12-22 2008-12-31 Ambrx Inc Modified human growth hormone
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
US20080227205A1 (en) * 2005-06-03 2008-09-18 Ambrx, Inc. Incorporation on Non-Naturally Encoded Amino Acids Into Proteins
KR20080026135A (ko) * 2005-06-03 2008-03-24 ì•”ëžŒëŁ©ìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ 개선된 읞간 ìží„°íŽ˜ëĄ  분자 및 읎의 용도
KR20080038391A (ko) * 2005-08-30 2008-05-06 녾볮 ë…žë„Žë””ìŠ€íŹ í—ŹìŠ€ 쌀얎 악티엔êČŒì €ìƒ€í”„íŠž 페귞화 성임 혞넎ëȘŹì˜ ì•ĄìČŽ 제제
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
JP2009519942A (ja) * 2005-12-14 2009-05-21 ă‚ąăƒłăƒ–ăƒ«ăƒƒă‚Żă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ éžć€©ç„¶ă‚ąăƒŸăƒŽé…žăŠă‚ˆăłăƒăƒȘăƒšăƒ—ăƒăƒ‰ă‚’ć«ă‚“ă§ă„ă‚‹ç”„æˆç‰©ă€ăă‚Œă‚‰ă«é–ąă™ă‚‹æ–čæł•ă€ăȘă‚‰ăłă«ă€ăă‚Œă‚‰ăźäœżç”š
KR20080081013A (ko) * 2005-12-30 2008-09-05 ì•”ëžŒëŁ©ìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ ëč„ìČœì—° ì•„ëŻžë…žì‚° 및 íŽëŠŹíŽ©í‹°ë“œë„Œ 핚유하는 ìĄ°ì„±ëŹŒ, 귞와ꎀ렚된 ë°©ëȕ 및 ê·ž 용도
EP1974025A4 (en) * 2006-01-19 2009-03-11 Ambrx Inc NON-NATURAL AMINO ACID POLYPEPTIDES WITH MODULATED IMMUNOGENICITY
US7776535B2 (en) * 2006-02-06 2010-08-17 Franklin And Marshall College Site-specific incorporation of fluorinated amino acids into proteins
CA2644474A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-ÎČ (IFN-ÎČ) POLYPEPTIDES
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL2007756T3 (pl) 2006-04-07 2016-01-29 Vertex Pharma Modulatory transporterĂłw posiadających kasetę wiÄ…ĆŒÄ…cą ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
WO2007130453A2 (en) * 2006-05-02 2007-11-15 Allozyne, Inc. Non-natural amino acid substituted polypeptides
JP2009538357A (ja) * 2006-05-26 2009-11-05 ă‚œă‚·ă‚šăƒ†ăƒ»ăƒ‰ă‚„ăƒ»ă‚łăƒłă‚»ă‚€ăƒŠăƒ»ăƒ‰ă‚„ăƒ»ăƒ«ă‚·ă‚§ăƒ«ă‚·ăƒ„ăƒ»ă‚šăƒ»ăƒ€ăƒ—ăƒȘă‚«ăƒŒă‚·ăƒ§ăƒłăƒ»ă‚·ăƒŁăƒłăƒ†ă‚Łăƒ•ă‚Łăƒƒă‚Żăƒ»ă‚šă‚čăƒ»ă‚ąăƒ»ă‚šă‚č 郚䜍ç‰čç•°çš„ïœïœ…ïœ‡ćŒ–æł•
AU2007271150A1 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
JP5570809B2 (ja) * 2006-09-01 2014-08-13 ノボ ăƒŽăƒ«ăƒ‡ă‚Łă‚čク ヘルă‚č ケス ă‚ąăƒŒă‚ČăƒŒ äżźéŁŸă‚żăƒłăƒ‘ă‚ŻèłȘ
KR100814822B1 (ko) * 2006-09-05 2008-03-20 삌성에슀디아읎 ìŁŒì‹íšŒì‚Ź 발ꎑ 임ìč˜, 읎의 ì œìĄ° ë°©ëȕ 및 읎 발ꎑ 임ìč˜ë„Œ íŹí•ší•˜ëŠ”ì•Ąì • 표시 임ìč˜
AU2013202770B2 (en) * 2006-09-08 2015-08-20 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
CN104193815A (zh) * 2006-09-08 2014-12-10 Ambrx慬揾 ç»äżźé„°çš„äșșç±»èĄ€æ”†ć€šè‚œæˆ–FcéȘšæž¶ć’Œć…¶ç”šé€”
AU2012203737B2 (en) * 2006-09-08 2014-06-19 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008073184A2 (en) 2006-10-18 2008-06-19 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
KR20140012199A (ko) * 2007-03-30 2014-01-29 ì•”ëžŒëŁ©ìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ 변형된 -21 íŽëŠŹíŽ©í‹°ë“œ 및 ê·ž 용도
NZ580686A (en) 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2195333A1 (en) * 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US7941707B2 (en) * 2007-10-19 2011-05-10 Oracle International Corporation Gathering information for use in diagnostic data dumping upon failure occurrence
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠윔얎 ìžìœ”íŹë ˆìŽí‹°ë“œ ïŒČ에 대한 변êČœëœ êČ°í•©ì„±ì„ 갖는  ëł€ìŽìČŽ
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
AU2013202836B8 (en) * 2008-07-23 2015-07-30 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
AU2009274076C1 (en) * 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
AU2013200271B2 (en) * 2008-09-26 2014-08-28 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
PL2342223T3 (pl) * 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
CN110317272A (zh) 2008-10-14 2019-10-11 éœć€«æ›Œ-æ‹‰çœ—ć„‡æœ‰é™ć…Źćž ć…ç–«çƒè›‹ç™œć˜äœ“ćŠć…¶ç”šé€”
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
JP5816097B2 (ja) * 2009-01-22 2015-11-18 ăƒŽăƒŽă‚©ăƒ»ăƒŽăƒ«ăƒ‡ă‚Łă‚čă‚Żăƒ»ăƒ˜ăƒ«ă‚čăƒ»ă‚±ă‚ąăƒ»ă‚ąăƒŒă‚ČăƒŒ 漉漚ăȘæˆé•·ăƒ›ăƒ«ăƒąăƒłćŒ–ćˆç‰©
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecĂ­ficos trivalentes
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
BR112012015461A2 (pt) * 2009-12-21 2017-01-10 Ambrx Inc polipeptĂ­deos de somatotropina boviina modificados e seus usos
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
SI2525834T1 (sl) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljơano in vivo učinkovitostjo
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
CA2790343A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
KR20190061096A (ko) 2010-04-22 2019-06-04 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ ì‹œíŽëĄœì•Œí‚ŹìčŽë„Žëł”ìŠ€ì•„ëŻžë„-읞돌 í™”í•©ëŹŒì˜ ì œìĄ° ë°©ëȕ
WO2011139391A1 (en) * 2010-04-28 2011-11-10 University Of Southern California Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans
US9770515B2 (en) 2010-06-01 2017-09-26 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of α-haloacetophenones, benzyl halides, quinones, and their derivatives
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
ES2742296T3 (es) 2010-08-17 2020-02-13 Ambrx Inc Polipéptidos de relaxina modificados y sus usos
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
EP3211421A1 (en) * 2010-09-09 2017-08-30 Traxxsson, LLC Combination methods of diagnosing cancer in a patient
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆çČ’çŽ°èƒžçŸ€èœćˆșæż€ć› ć­ćŠć…¶èźŠé«”äč‹èȘżé…ç‰©
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteĂ­nas de ligação de antĂ­geno, composição farmacĂȘutica, uso de uma proteĂ­na de ligação de antĂ­geno, mĂ©todo para o tratamento de um paciente e mĂ©todo para a preparação de uma proteĂ­na de ligação de antĂ­geno, ĂĄcido nucleico, vetor e cĂ©lula hospedeira"
KR20160044598A (ko) 2011-03-29 2016-04-25 ëĄœìŠˆ êž€ëŠŹìčŽíŠž 아êȌ 항ìČŽ Fc ëł€ìŽìČŽ
DK2736533T3 (en) 2011-07-29 2018-08-06 Avelas Biosciences Inc SELECTIVE SUBMISSION MOLECULES AND METHODS OF USE
US9558645B2 (en) 2012-01-06 2017-01-31 3M Innovative Properties Company Released offender geospatial location information trend analysis
BR112014016607A8 (pt) 2012-01-06 2017-07-04 3M Innovative Properties Co central de informaçÔes de localização geoespacial de criminosos liberados
BR112014016758A8 (pt) 2012-01-06 2017-07-04 3M Innovative Properties Co aplicativo de usuårio para informação sobre localização geoespacial de infratores em liberdade
EP2809400B1 (en) * 2012-02-03 2018-11-07 Antisense Therapeutics Ltd Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
CN104582736A (zh) 2012-06-21 2015-04-29 捰第漉çșłć€§ć­Šç ”ç©¶ćŠç§‘æŠ€æœ‰é™ć…Źćž Fc效ćș”ć­ćŠŸèƒœæ”čć˜çš„è‚ é™èĄ€çł–çŽ ć—äœ“é…äœ“ć€šè‚œFcćŒșèžćˆć€šè‚œć’ŒçŒ€ćˆç‰©
JP6309002B2 (ja) 2012-06-27 2018-04-11 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒïŒŠïŒŽ ïŒšïœïœ†ïœ†ïœïœïœŽïœŽâˆ’ïŒŹïœ ïŒČ ïŒĄïœ‹ïœ”ïœ‰ïœ…ïœŽïœ‡ïœ…ïœ“ïœ…ïœŒïœŒïœ“ïœƒïœˆïœïœ†ïœ” æš™çš„ă«ç‰čç•°çš„ă«ç”ćˆă™ă‚‹ć°‘ăȘăăšă‚‚ïŒ‘ă€ăźç”ćˆćźŸäœ“ă‚’ć«ă‚€æŠ—äœ“ïŒŠïœƒé ˜ćŸŸç”ćˆäœ“ă‚’äœœèŁœă™ă‚‹ăŸă‚ăźæ–čæł•ăŠă‚ˆăłăăźäœżç”š
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
UA120029C2 (uk) 2012-07-13 2019-09-25 Đ ĐŸŃˆ ГліĐșарт Аг ĐĄĐżĐŸŃŃ–Đ± Đ·ĐœĐžĐ¶Đ”ĐœĐœŃ ĐČ'ŃĐ·ĐșĐŸŃŃ‚Ń– Đ±Ń–ŃĐżĐ”Ń†ĐžŃ„Ń–Ń‡ĐœĐŸĐłĐŸ Đ°ĐœŃ‚ĐžŃ‚Ń–Đ»Đ° ĐŽĐŸ vegf/ang-2 та Đ·Đ°ŃŃ‚ĐŸŃŃƒĐČĐ°ĐœĐœŃ таĐșĐŸĐłĐŸ Đ°ĐœŃ‚ĐžŃ‚Ń–Đ»Đ° ĐŽĐ»Ń ліĐșуĐČĐ°ĐœĐœŃ ŃŃƒĐŽĐžĐœĐœĐžŃ… ĐŸŃ‡ĐœĐžŃ… Đ·Đ°Ń…ĐČĐŸŃ€ŃŽĐČĐ°ĐœŃŒ
CA2878057A1 (en) 2012-07-16 2014-01-23 Rossitza Gueorguieva Alargova Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2014035364A2 (en) * 2012-08-27 2014-03-06 Empire Technology Development Llc Gelatin alkyd peptides and uses thereof
WO2014078866A2 (en) 2012-11-19 2014-05-22 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
JP6508781B2 (ja) 2013-01-30 2019-05-08 ă‚ąăƒ™ăƒ©ă‚č ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ăƒŒă‚șïŒŒă‚€ăƒłă‚ŻïŒŽ 遞択的ăȘé€é”ćˆ†ć­ćŠăłăăźäœżç”šæ–čæł•
EP3587448B1 (en) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
CN105120887A (zh) 2013-04-05 2015-12-02 èŻș撌èŻșćŸ·äżć„è‚Ąä»œæœ‰é™ć…Źćž ç”Ÿé•żæż€çŽ ćŒ–ćˆç‰©ćˆ¶ć‰‚
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de uniĂłn a FcRn humano y procedimientos de uso
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ Fc-수용ìČŽ êČ°í•© 개질된 ëč„대ìč­ í•­ìČŽ 및 읎의 ì‚Źìš© ë°©ëȕ
RS59991B1 (sr) 2013-08-08 2020-04-30 Scripps Research Inst Metoda enzimskog in vitro obeleĆŸavanja specifičnog za poloĆŸaj nukleinskih kiselina uvođenjem neprirodnih nukleotida
RU2016115866A (ru) 2013-10-11 2017-11-16 Đ€. Đ„ĐŸŃ„Ń„ĐŒĐ°ĐœĐœ-Ля Đ ĐŸŃˆ Аг ĐœŃƒĐ»ŃŒŃ‚ĐžŃĐżĐ”Ń†ĐžŃ„ĐžŃ‡Đ”ŃĐșОД Đ°ĐœŃ‚ĐžŃ‚Đ”Đ»Đ° с ĐŸĐ±ĐŒĐ”ĐœŃĐœĐœŃ‹ĐŒĐž ĐŽĐŸĐŒĐ”ĐœĐ°ĐŒĐž Đž ĐŸĐŽĐžĐœĐ°ĐșĐŸĐČŃ‹ĐŒĐž ĐČĐ°Ń€ĐžĐ°Đ±Đ”Đ»ŃŒĐœŃ‹ĐŒĐž ĐŽĐŸĐŒĐ”ĐœĐ°ĐŒĐž лДгĐșĐŸĐč цДпО
CN106029087A (zh) 2013-12-20 2016-10-12 捰第漉çșłć€§ć­Šç ”ç©¶ćŠç§‘æŠ€æœ‰é™ć…Źćž è„‚èŽšćŒ–è‚ é™èĄ€çł–çŽ ć—äœ“é…äœ“äșșć…ç–«çƒè›‹ç™œfcćŒșèžćˆć€šè‚œ
CN105899534B (zh) 2014-01-15 2020-01-07 è±Șć€«èżˆÂ·çœ—æ°æœ‰é™ć…Źćž ć…·æœ‰äżźé„°çš„FCRNć’ŒäżæŒçš„è›‹ç™œAç»“ćˆæ€§èŽšçš„FcćŒșć˜äœ“
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos especĂ­ficos que se ligam a cd38 e cd3
HUE056155T2 (hu) 2014-04-09 2022-01-28 Scripps Research Inst Nem-természetes vagy módosított nukleozid-trifoszfåtok sejtekbe importålåsa nukleinsav-trifoszfåt transzporterekkel
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których poƛredniczy mukowiscydozowy przezbƂonowy regulator przewodnictwa
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에읎ëč„옚 ìŁŒì‹íšŒì‚Ź 페Ꞟ화된 ìží„°íŽ˜ëĄ  -ëȠ타 ëł€ìŽìČŽ
CN107108710B (zh) 2014-10-24 2022-02-15 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž äżźé„°çš„fgf-21ć€šè‚œćŠć…¶ç”šé€”
BR112017006591A2 (pt) 2014-11-06 2018-01-16 Hoffmann La Roche polipeptĂ­deo heterodimĂ©rico, formulação farmacĂȘutica e uso de um polipeptĂ­deo heterodimĂ©rico
BR112017006178A2 (pt) 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag regiĂŁo fc, anticorpos, formulação farmacĂȘutica e usos dos anticorpos
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
KR102689285B1 (ko) 2014-11-26 2024-07-31 젠윔얎 ìžìœ”íŹë ˆìŽí‹°ë“œ ïŒŁïœ„3 및 ìą…ì–‘ í•­ì›êłŒ êČ°í•©í•˜ëŠ” ìŽìą…ìŽëŸ‰ìČŽ 항ìČŽ
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor慬揾 ç»“ćˆcd3撌cd38çš„ćŒ‚äșŒèšäœ“抗䜓
JP6721590B2 (ja) 2014-12-03 2020-07-15 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒïŒŠïŒŽ ïŒšïœïœ†ïœ†ïœïœïœŽïœŽâˆ’ïŒŹïœ ïŒČ ïŒĄïœ‹ïœ”ïœ‰ïœ…ïœŽïœ‡ïœ…ïœ“ïœ…ïœŒïœŒïœ“ïœƒïœˆïœïœ†ïœ” ć€šé‡ç‰č異性抗䜓
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US9945132B2 (en) * 2015-04-24 2018-04-17 Axia Acquisition Corporation Finisher box with blade assembly
TN2017000470A1 (en) 2015-05-08 2019-04-12 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens.
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3960765A1 (en) 2015-06-26 2022-03-02 Sanofi Biotechnology SAS Monoclonal anti-il-1racp antibodies
US20170007711A1 (en) * 2015-07-07 2017-01-12 Richard S. Brody Pegylated growth hormone antagonists
US10874717B2 (en) 2015-07-07 2020-12-29 Burr Oak Therapeutics LLC Pegylated growth hormone antagonists
US20170101437A1 (en) * 2015-10-09 2017-04-13 Hetero Drugs Ltd. Process for purification of darbepoetin alfa
AU2016344665C1 (en) 2015-10-29 2023-07-27 F. Hoffmann-La Roche Ag Anti-variant Fc-region antibodies and methods of use
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
BR112018069890A2 (pt) 2016-05-02 2019-02-05 Hoffmann La Roche polipeptĂ­dio de fusĂŁo que se liga de forma especĂ­fica a um alvo, polipeptĂ­dio de fusĂŁo dimĂ©rico, ĂĄcido nucleico isolado, par de ĂĄcidos nucleicos isolados, cĂ©lula hospedeira, mĂ©todo para produzir um polipeptĂ­dio de fusĂŁo, imunoconjugado, formulação farmacĂȘutica, polipeptĂ­dio de fusĂŁo e uso do polipeptĂ­dio de fusĂŁo
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US20170349657A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
EP3464365A1 (en) 2016-06-01 2019-04-10 Xencor, Inc. Bispecific antibodies that bind cd123 and cd3
ES2793773T3 (es) 2016-06-20 2020-11-16 Elanco Us Inc Interferón porcino pegilado y métodos de utilización del mismo
DK3475295T3 (da) 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportĂžr og anvendelser deraf
CN112274637A (zh) 2016-08-17 2021-01-29 ćș·ć§†æ™źæ čæœ‰é™ć…Źćž 抗tigitæŠ—äœ“ă€æŠ—pvrigæŠ—äœ“ćŠć…¶ç»„ćˆ
CN109689079A (zh) 2016-08-22 2019-04-26 äŒŠć…°ç§‘çŸŽć›œć…Źćž 牛成çș€ç»Žç»†èƒžç”Ÿé•żć› ć­21撌äčłç•œäž­çš„é…źç—…
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11201903302UA (en) 2016-10-14 2019-05-30 Xencor Inc Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018129522A1 (en) 2017-01-09 2018-07-12 Torch Therapeutics Conditionally effective bispecific therapeutics
KR102670432B1 (ko) 2017-02-08 2024-05-28 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 앜동학적 읞핞서넌 포핹하는 변형된 렐띜신 íŽëŠŹíŽ©í‹°ë“œ 및 귞의 용도
CN108623695B (zh) * 2017-03-24 2022-03-15 äž­ć›œç§‘ć­Šé™ąèż‡çš‹ć·„çš‹ç ”ç©¶æ‰€ äž€ç§ç™œè›‹ç™œç»“ćˆè‚œ-äșșç«çŠ¶ç„žç»è„ć…»ć› ć­èžćˆè›‹ç™œćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
KR20200041834A (ko) 2017-06-01 2020-04-22 젠윔얎 ìžìœ”íŹë ˆìŽí‹°ë“œ Cd123 및 cd3에 êČ°í•©í•˜ëŠ” 읎쀑íŠč읎성 항ìČŽ
SG10202111336RA (en) 2017-06-01 2021-11-29 Compugen Ltd Triple combination antibody therapies
WO2018232406A1 (en) * 2017-06-16 2018-12-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods, systems, and compositions for legume-based production of therapeutic proteins and therapeutic medical materials.
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
IL271903B2 (en) 2017-07-11 2025-04-01 Synthorx Inc Combination of unnatural nucleotides and methods therefor
SG11202000939PA (en) * 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019040498A1 (en) * 2017-08-21 2019-02-28 University Of Delaware PEPTIDE MACROMOLECULAR ASSEMBLIES
AR113756A1 (es) 2017-10-11 2020-06-10 Ambrx Inc Variantes porcinas de g-csf y sus usos
JP2021500930A (ja) 2017-11-01 2021-01-14 ă‚šăƒ•ïŒŽăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒ„ ă‚ąăƒŒă‚ČăƒŒïŒŠïŒŽ ïŒšïœïœ†ïœ†ïœïœïœŽïœŽâˆ’ïŒŹïœ ïŒČ ïŒĄïœ‹ïœ”ïœ‰ïœ…ïœŽïœ‡ïœ…ïœ“ïœ…ïœŒïœŒïœ“ïœƒïœˆïœïœ†ïœ” ïŒŁïœïœïœăƒœăƒ‡ă‚Łâˆ’ć€šäŸĄæš™çš„ç”ćˆç‰©èłȘ
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CA3087234A1 (en) 2017-12-29 2019-07-04 The Scripps Research Institute Unnatural base pair compositions and methods of use
MX2020008219A (es) 2018-02-08 2020-10-22 Amgen Inc Formulacion farmaceutica de ph bajo.
WO2019165453A1 (en) * 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
HUE068337T2 (hu) 2018-03-29 2024-12-28 Ambrx Inc Humanizålt, prosztataspecifikus membrånantigén (PSMA) elleni ellenanyag-hatóanyag konjugåtumok
JP7724061B2 (ja) 2018-04-11 2025-08-15 ă‚€ăƒłăƒ’ăƒ–ăƒ«ă‚Żă‚č ăƒă‚€ă‚Șă‚”ă‚€ă‚šăƒłă‚·ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ćˆ¶çŽ„ă•ă‚ŒăŸïœƒïœ„ïŒ“ç”ćˆă‚’æœ‰ă™ă‚‹ć€šé‡ç‰čç•°æ€§ăƒăƒȘăƒšăƒ—ăƒăƒ‰æ§‹çŻ‰ç‰©ăȘらびに閹連するæ–čæł•ăŠă‚ˆăłäœżç”š
JP2021520829A (ja) 2018-04-18 2021-08-26 ă‚Œăƒłă‚łă‚ą ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ©ïŒŹâˆ’ïŒ‘ïŒ•ïŒïŒ©ïŒŹâˆ’ïŒ‘ïŒ•ïŒČïŒĄ ïŒŠïœƒèžćˆă‚żăƒłăƒ‘ă‚ŻèłȘăŠă‚ˆăłïŒŽïŒ©ïŒ­âˆ’ïŒ“æŠ—ćŽŸç”ćˆăƒ‰ăƒĄă‚€ăƒłă‚’ć«ă‚€ă€ïŒŽïŒ©ïŒ­âˆ’ïŒ“æš™çš„ćŒ–ăƒ˜ăƒ†ăƒ­äșŒé‡äœ“èžćˆă‚żăƒłăƒ‘ă‚ŻèłȘ
CN112867734A (zh) 2018-04-18 2021-05-28 Xencorè‚Ąä»œæœ‰é™ć…Źćž ćŒ…ć«IL-15/IL-15Ra Fcèžćˆè›‹ç™œć’ŒPD-1æŠ—ćŽŸç»“ćˆç»“æž„ćŸŸçš„é¶ć‘PD-1çš„ćŒ‚æșäșŒèšäœ“èžćˆè›‹ç™œćŠć…¶ç”šé€”
IL278090B2 (en) 2018-04-18 2024-07-01 Xencor Inc Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
AU2019256520A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and LAG-3 antigen binding domains
US20210230281A1 (en) 2018-04-27 2021-07-29 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
US20210231651A1 (en) * 2018-04-30 2021-07-29 Genalyte, Inc. Methods and compositions for point of care measurement of the bioavailability of therapeutic biologics
SG11202010439VA (en) 2018-05-01 2020-11-27 Ambrx Inc A method for optimizing antibody expression
CA3101019A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
EP3801617A1 (en) 2018-06-01 2021-04-14 Novartis Ag Dosing of a bispecific antibody that bind cd123 and cd3
BR112020026724A2 (pt) 2018-07-02 2021-03-30 Amgen Inc. Proteína de ligação ao antígeno anti-steap1
WO2020018556A1 (en) 2018-07-16 2020-01-23 Amgen Inc. Method of treating multiple myeloma
CA3116188A1 (en) 2018-10-12 2020-04-16 Xencor, Inc. Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
WO2020082057A1 (en) * 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN109439606B (zh) * 2018-11-14 2022-06-28 äž­ć›œç§‘ć­Šé™ąé’ćČ›ç”Ÿç‰©èƒœæșäžŽèż‡çš‹ç ”究所 äž€ç§æé«˜é—Žè‹Żäž‰é…šäș§é‡çš„ćŸșć› ć·„çš‹èŒćŠć…¶æž„ć»șæ–čæł•äžŽćș”甚
EP3893919A4 (en) 2018-12-11 2022-11-30 Molecular Technologies Laboratories LLC PEGYLATED GROWTH HORMONE ANTAGONISTS
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3914358A1 (en) 2019-01-23 2021-12-01 Millennium Pharmaceuticals, Inc. Anti-cd38 antibodies
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
AU2020291535A1 (en) 2019-06-14 2022-01-20 The Scripps Research Institute Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
WO2020257243A1 (en) * 2019-06-17 2020-12-24 Molecular Technologies Laboratories Llc Therapeutic pegylated growth hormone antagonists
US11857602B2 (en) * 2019-06-17 2024-01-02 Molecular Technologies Laboratories Llc Growth hormone antagonist and anti-cancer composition combination therapy
TW202124385A (zh) 2019-09-10 2021-07-01 çŸŽć•†æŹŁçˆć…‹æ–Żć…Źćž æȻ療è‡Șé«”ć…ç–«ç–Ÿç—…äč‹il-2æŽ„ćˆç‰©ćŠäœżç”šæ–čæł•
TW202128757A (zh) 2019-10-11 2021-08-01 çŸŽć•†ć»șć—ćŸ·ć…‹ć…Źćž ć…·æœ‰æ”č斄äč‹ç‰č性的 PD-1 暙靶 IL-15/IL-15Rα FC èžćˆè›‹ç™œ
US20240228573A9 (en) * 2019-10-17 2024-07-11 Jcr Pharmaceuticals Co., Ltd. Method for producing fusion protein of serum albumin and growth hormone
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
TW202136318A (zh) 2020-01-28 2021-10-01 çŸŽć•†ć»șć—ćŸ·ć…‹ć…Źćž 甚斌æČ»ç™‚ç™Œç—‡çš„ IL15/IL15R α 異äșŒèšé«” Fc èžćˆè›‹ç™œèłȘ
TW202146452A (zh) 2020-02-28 2021-12-16 ç‘žćŁ«ć•†è«ŸèŻć…Źćž ç”ćˆïœƒïœ„ïŒ‘ïŒ’ïŒ“ć’Œïœƒïœ„ïŒ“äč‹é›™ç‰č異性抗體的甊藄
MX2022012208A (es) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
CN111938655B (zh) * 2020-07-09 2021-09-03 䞊攷äș€é€šć€§ć­Š ćŸșäșŽć…łé”źç‚čäżĄæŻçš„çœŒçœ¶èœŻç»„ç»‡ćœąæ€èŻ„ä»·æ–čæł•ă€çł»ç»ŸćŠèźŸć€‡
CN116472288A (zh) 2020-11-06 2023-07-21 èŻșćŽè‚Ąä»œæœ‰é™ć…Źćž 抗䜓Fcć˜äœ“
US20240374735A1 (en) 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
US11688595B2 (en) 2020-11-20 2023-06-27 Thermo Finnigan Llc Operating a mass spectrometer for sample quantification
EP4265637A4 (en) 2020-12-18 2025-01-15 Zhuhai Trinomab Pharmaceutical Co., Ltd. RESPIRATORY SYNCYTIAL VIRUS SPECIFIC BINDING MOLECULE
WO2022140701A1 (en) 2020-12-24 2022-06-30 Xencor, Inc. Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains
US20250332264A1 (en) 2021-06-18 2025-10-30 Peptidream Inc. GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME
IL310372A (en) 2021-07-28 2024-03-01 Genentech Inc Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
WO2023015198A1 (en) 2021-08-04 2023-02-09 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
AU2022328512A1 (en) * 2021-08-18 2024-03-28 Remd Biotherapeutics, Inc. Novel interferon variants and bifunctional fusion molecules thereof
CN117858905A (zh) 2021-08-19 2024-04-09 è±Șć€«èżˆÂ·çœ—æ°æœ‰é™ć…Źćž ć€šä»·æŠ—ć˜äœ“fcćŒșæŠ—äœ“ćŠäœżç”šæ–čæł•
CN114107394B (zh) * 2021-11-05 2024-01-30 äž­ć›œç§‘ć­Šé™ąçČŸćŻ†æ”‹é‡ç§‘ć­ŠäžŽæŠ€æœŻćˆ›æ–°ç ”ç©¶é™ą äž€ç§æ…ąç—…æŻ’èœŹç§»èœœäœ“ă€èĄšèŸŸPylRS揊tRNACUAçš„ç»†èƒžçł»ćŠćˆ¶ć€‡æ–čæł•äžŽćș”甚
EP4493208A1 (en) 2022-03-17 2025-01-22 Astrazeneca Ireland Limited Improved igg-degrading enzymes and methods of use thereof
WO2023196905A1 (en) 2022-04-07 2023-10-12 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
US12139502B2 (en) 2022-05-18 2024-11-12 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
CN120344270A (zh) 2022-10-07 2025-07-18 Ambrx 慬揾 èŻç‰©æŽ„ć€ŽćŠć…¶æŠ—äœ“çŒ€ćˆç‰©
WO2024098023A2 (en) * 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
CN120882432A (zh) 2023-01-16 2025-10-31 Ambrx 慬揾 抗cd70抗䜓-èŻç‰©çŒ€ćˆç‰©
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof
WO2024248867A1 (en) 2023-05-31 2024-12-05 Genentech, Inc. Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies
WO2025041055A1 (en) 2023-08-22 2025-02-27 Ambrx, Inc. Anti-psma adc conjugate compositions and methods of use thereof

Family Cites Families (398)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US85619A (en) * 1869-01-05 Improvement in machine for sowing pulverulent manures
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4241174A (en) 1978-11-24 1980-12-23 Hoffmann-La Roche Inc. Interferon assay
IN150740B (enExample) 1978-11-24 1982-12-04 Hoffmann La Roche
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US6410697B1 (en) 1979-04-20 2002-06-25 Schering Corporation Process for purifying human leukocyte interferon
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4898830A (en) 1979-07-05 1990-02-06 Genentech, Inc. Human growth hormone DNA
US5554513A (en) 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
IL58765A (en) 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
YU45104B (en) 1980-04-03 1992-03-10 Biogen Nv Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
NZ198445A (en) 1980-09-25 1984-05-31 Genentech Inc Production of human fibroblast interferon by recombinant dna technology
EP0064063B1 (en) 1980-11-07 1985-09-11 Celltech Limited Assay for interferon
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur DurchfĂŒhrung des Verfahrens
US4364863A (en) 1980-12-29 1982-12-21 Schering Corporation Extraction of interferon from bacteria
WO1982002715A1 (fr) 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4614651A (en) 1981-07-12 1986-09-30 Damon Biotech, Inc. Interferon epsilon
US4810645A (en) 1981-08-14 1989-03-07 Hoffmann-La Roche Inc. Microbial production of mature human leukocyte interferon K and L
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US5096705A (en) 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US5582824A (en) 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトÎČćž‹ă‚€ăƒłă‚żâˆ’ăƒ•ă‚šăƒ­ăƒłéșäŒć­ă‚’ć«ă‚€ç”„ăżă‹ăˆäœ“ăƒ—ăƒ©ă‚čミド
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp ăƒ‡âˆ’ă‚żć‡Šç†èŁ…çœź
US5098703A (en) 1982-01-15 1992-03-24 Cetus Corporation Interferon-alpha 76
US4975276A (en) 1982-01-15 1990-12-04 Cetus Corporation Interferon-alpha 54
US4973479A (en) 1982-01-15 1990-11-27 Cetus Corporation Interferon-α61
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
US4446235A (en) 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
EP0092227B1 (en) 1982-04-19 1988-07-27 Nissan Motor Co., Ltd. Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 MĂŒnchen Arzneimittel zur tumorbehandlung
DE3220116A1 (de) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wÀssriger Phase
IL66733A (en) 1982-09-07 1986-03-31 Yeda Res & Dev Assay for ifn and kit therefor
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-ÎČ muteins
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4432895A (en) 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新芏ăȘç™șçŸćž‹ăƒ—ăƒ©ă‚čăƒŸăƒ‰ăšăă‚Œă‚‰ă‚’ç”šă„ăŠä»”ç‰›ăƒ—ăƒ­ă‚­ăƒąă‚·ăƒłéșäŒć­ă‚’ć€§è…žèŒć†…ă§ç™șçŸă•ă›ă‚‹æ–čæł•
US4859600A (en) 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4921699A (en) 1983-06-01 1990-05-01 Hoffman-La Roche Inc. Polypeptides having interferon activity
US4816566A (en) 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JP2551746B2 (ja) 1983-07-19 1996-11-06 ă‚”ăƒłăƒˆăƒȘăƒŒæ ȘćŒäŒšç€Ÿ æ”čè‰Żăƒ—ăƒ©ă‚čăƒŸăƒ‰ăƒ™ă‚Żă‚żâˆ’ăŠă‚ˆăłăăźćˆ©ç”š
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
US4681930A (en) 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
FR2556365B1 (fr) 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
EP0164556B1 (en) 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
GB8412564D0 (en) 1984-05-17 1984-06-20 Searle & Co Structure and properties
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US4675282A (en) 1984-07-06 1987-06-23 Damon Biotech, Inc. Assay for interferon epsilon
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd æ–°èŠăƒ’ăƒˆă‚€ăƒłă‚żâˆ’ăƒ•ă‚šăƒ­ăƒłâˆ’ïœ’ăƒăƒȘペプチドèȘ˜ć°Žäœ“
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
JPS6156199A (ja) 1984-08-27 1986-03-20 Shionogi & Co Ltd æ–°èŠăƒ’ăƒˆă‚€ăƒłă‚żâˆ’ăƒ•ă‚šăƒ­ăƒłÎ±éĄž
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4963495A (en) 1984-10-05 1990-10-16 Genentech, Inc. Secretion of heterologous proteins
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4665180A (en) 1984-11-06 1987-05-12 Petrolite Corporation Substituted tetrahydropyrimidines and octahydrophenanthridines
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
EP0188256B1 (en) 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
GB8510893D0 (en) * 1985-04-30 1985-06-05 Cpc International Inc Starch separation process
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4636674A (en) * 1985-07-19 1987-01-13 Allied Corporation Linear flux switch alternator
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5516515A (en) 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE72582T1 (de) 1986-09-05 1992-02-15 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
JPS63123383A (ja) 1986-11-11 1988-05-27 Mitsubishi Kasei Corp ăƒă‚€ăƒ–ăƒȘツドプロヱ−タ−、ç™ș珟èȘżçŻ€ïœ„ïœŽïœé…ćˆ—ăŠă‚ˆăłç™șçŸăƒ™ă‚Żă‚żâˆ’
US4894330A (en) 1986-12-23 1990-01-16 Cetus Corporation Purification of recombinant beta-interferon incorporating RP-HPLC
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US4908432A (en) 1987-01-09 1990-03-13 New York University Novel polypeptide having gamma-interferon activity
US5190751A (en) 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
WO1988007082A1 (en) 1987-03-16 1988-09-22 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
ATE103333T1 (de) 1987-03-23 1994-04-15 Zymogenetics Inc Hohe proteinsyntheserate in hefe.
DE3712564A1 (de) 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5688763A (en) 1987-06-12 1997-11-18 Hammonds, Jr.; R. Glenn Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
AU2136788A (en) 1987-07-24 1989-03-01 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
WO1989001038A1 (en) 1987-07-24 1989-02-09 Cetus Corporation PRODUCTION OF BIOLOGICALLY ACTIVE FORMS OF CSF USING A BACULOVIRUS (AcNPV)-INSECT CELL EXPRESSION SYSTEM
IT1222427B (it) 1987-07-31 1990-09-05 Sclavo Spa Procedimento per la purificazione di interferone
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1335792C (en) 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5192669A (en) 1987-11-09 1993-03-09 Eli Lilly And Company Method to produce recombinant proteins using an expression vector comprising transcriptional and translational activating sequences
US5063158A (en) 1987-11-09 1991-11-05 Eli Lilly And Company Recombinant DNA expression vector comprising both transcriptional and translational activating sequences
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
AU4197389A (en) 1988-08-05 1990-03-05 Mount Sinai School Of Medicine Of The City University Of New York, The In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
SE462364B (sv) 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5688666A (en) 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2345497A1 (en) 1988-10-28 1990-04-28 Genentech, Inc. Growth hormone variants and method for forming growth hormone variants
US4959210A (en) 1988-11-01 1990-09-25 Schering Corporation Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
WO1990005785A1 (en) 1988-11-18 1990-05-31 The Regents Of The University Of California Method for site-specifically incorporating unnatural amino acids into proteins
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5268169A (en) 1989-02-02 1993-12-07 Roussel Uclaf Treatment method of ovarian cancer using interferon gamma
WO1990010078A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
WO1990010277A1 (en) 1989-02-24 1990-09-07 Cell Analysis Systems, Inc. Method and apparatus for determining a proliferation index of a cell sample
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
US5196191A (en) 1989-03-17 1993-03-23 Genentech, Inc. Temporal gamma-interferon administration for allergies
IL89662A (en) 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
HUT64022A (en) 1989-04-19 1993-11-29 Enzon Inc Process for producing active polyalkileneoxide carbonates for the modification of polypeptides
CA2033070A1 (en) 1989-05-17 1990-11-18 Lois K. Miller Baculovirus expression vectors
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma FremgangsmÄde til fremstilling af polyethylenglycolderivater og modificeret protein
US5391713A (en) 1989-06-20 1995-02-21 Bionative Ab Interferon purification process
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
AU6643690A (en) 1989-10-23 1991-05-16 Schering Corporation Polypeptide inhibitors of gamma interferon
US5162601A (en) 1989-11-22 1992-11-10 The Upjohn Company Plant potyvirus expression vector with a gene for protease
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US4989830A (en) * 1990-01-26 1991-02-05 Ratnik Industries, Inc. Motorized hydrant
US5849282A (en) 1990-05-09 1998-12-15 Otsuka Pharmaceutical Co., Ltd. Method of treating colon, renal, and lung carcinomas with Îł-interferon and Ser71 !-interleukin-1ÎČ
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
HUT63185A (en) 1990-06-04 1993-07-28 Schering Corp Process for producing crystalline alpha-2-interferon
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
CA2088599A1 (en) 1990-08-02 1992-02-03 Carol A. Pachl Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
FR2665923B1 (fr) 1990-08-14 1993-01-22 Arbona Jean Unite de soins modulaire.
US5594107A (en) 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
JP3051145B2 (ja) 1990-08-28 2000-06-12 äœć‹èŁœè–Źæ ȘćŒäŒšç€Ÿ 新芏ăȘポăƒȘスチレングăƒȘă‚łăƒŒăƒ«èȘ˜ć°Žäœ“äżźéŁŸăƒšăƒ—ăƒăƒ‰
CA2090969C (en) 1990-09-04 2001-08-21 Russell Arthur Brierley Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5492821A (en) 1990-11-14 1996-02-20 Cargill, Inc. Stabilized polyacrylic saccharide protein conjugates
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5378823A (en) 1990-11-29 1995-01-03 Institut National De La Recherche Agronomique-I.N.R.A. Nucleic acids encoding type I interferon variants
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6013433A (en) 1991-04-26 2000-01-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
EP0586549B1 (en) * 1991-05-10 2000-09-20 Genentech, Inc. Selecting ligand agonists and antagonists
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
DE4128319A1 (de) 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
KR940006679B1 (ko) 1991-09-26 1994-07-25 현대전자산업 ìŁŒì‹íšŒì‚Ź 수직형 튞랜지슀터넌 갖는 dram셀 및 ê·ž ì œìĄ°ë°©ëȕ
US5863530A (en) 1991-10-11 1999-01-26 Spruson & Ferguson Treating ophthalmic fibrosis using interferon-α
US5540923A (en) 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
EP0551535A1 (en) 1992-01-13 1993-07-21 SCLAVO S.p.A. Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
DE69312700T2 (de) 1992-04-14 1998-02-19 Cornell Res Foundation Inc MakromolekĂŒle auf basis von dendritischen polymeren und verfahren zur herstellung
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5591974A (en) 1992-09-30 1997-01-07 Westinghouse Electric Corporation Automated collection and processing of environmental samples
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015624A1 (en) 1993-01-08 1994-07-21 The Population Council Use of sulphated polysaccharides for preventing sexually transmitted diseases
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5532142A (en) 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or ÎČ-i
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5789551A (en) 1993-06-11 1998-08-04 Pestka Biomedical Laboratories, Inc. Human leukocyte interferon Hu-IFN-α001
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5491076A (en) 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
AU691225B2 (en) 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US5624895A (en) 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
DK0741577T3 (da) 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lĂŠgemidler til behandling af virusinfektioner i leveren
US5545723A (en) 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-ÎČ
JP3090586B2 (ja) 1994-03-15 2000-09-25 ç‰‡ć€‰ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚·ă‚čăƒ†ă‚€ăƒłăƒ—ăƒ­ăƒ†ă‚ąăƒŒă‚ŒéșäŒć­æŹ æăƒă‚­ăƒ„ăƒ­ă‚Šă‚€ăƒ«ă‚čăŠă‚ˆăłăăźèŁœé€ æł•äžŠăłă«ă“ă‚Œă‚’ćˆ©ç”šă™ă‚‹æœ‰ç”šă‚żăƒłăƒ‘ă‚ŻèłȘăźèŁœé€ æł•
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5686110A (en) 1994-06-02 1997-11-11 Enzon, Inc. Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3467515B2 (ja) 1994-11-01 2003-11-17 èČĄć›Łæł•äșșăƒ«ă‚€ăƒ»ăƒ‘ă‚čăƒˆă‚„ăƒŒăƒ«ćŒ»ć­Šç ”ç©¶ă‚»ăƒłă‚żăƒŒ ă‚€ăƒłă‚żăƒŒăƒ•ă‚§ăƒ­ăƒłæŽ»æ€§ăźæžŹćźšæł•
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6183987B1 (en) 1995-02-17 2001-02-06 Stichting Institut Voor Dierhouderij En Diergezonheld Production of biologically active recombinant bovine follicle stimulation hormone (rec bFSH) in the baculovirus expression system
FR2732035B1 (fr) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
JP2758154B2 (ja) 1995-04-06 1998-05-28 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłâˆ’ăƒ© ăƒ­ă‚·ăƒŠ ă‚ąăƒŒă‚ČăƒŒ ă‚€ăƒłă‚żăƒŒăƒ•ă‚§ăƒ­ăƒłă‚’ć«ă‚€æ¶Čäœ“èŁœć‰€
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
US5770191A (en) 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5814485A (en) 1995-06-06 1998-09-29 Chiron Corporation Production of interferon-ÎČ (IFN-ÎČ) in E. coli
AU5893696A (en) 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5780027A (en) 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
DE19535853C2 (de) 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69635026T2 (de) 1995-09-21 2006-05-24 Genentech Inc., San Francisco Varianten des menschlichen wachstumshormons
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU1690697A (en) 1996-01-17 1997-08-11 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin antagonists
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
AU728146B2 (en) 1996-03-14 2001-01-04 Immune Response Corporation, The Targeted delivery of genes encoding interferon
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US5831062A (en) 1996-05-09 1998-11-03 Amgen Inc. Use of the human interferon consensus gene for gene therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RU2199347C2 (ru) 1996-08-02 2003-02-27 ĐžŃ€Ń‚ĐŸ-МаĐșĐœĐ”ĐčĐ» Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșĐ°Đ», Đ˜ĐœĐș. ĐŸĐŸĐ»ĐžĐżĐ”ĐżŃ‚ĐžĐŽŃ‹, ĐŸĐ±Đ»Đ°ĐŽĐ°ŃŽŃ‰ĐžĐ” Đ”ĐŽĐžĐœŃŃ‚ĐČĐ”ĐœĐœŃ‹ĐŒ ĐșĐŸĐČĐ°Đ»Đ”ĐœŃ‚ĐœĐŸ сĐČŃĐ·Đ°ĐœĐœŃ‹ĐŒ n-ĐșĐŸĐœŃ†Đ”ĐČŃ‹ĐŒ ĐČĐŸĐŽĐŸŃ€Đ°ŃŃ‚ĐČĐŸŃ€ĐžĐŒŃ‹ĐŒ ĐżĐŸĐ»ĐžĐŒĐ”Ń€ĐŸĐŒ
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5998595A (en) 1996-11-05 1999-12-07 Wako Pure Chemical Industries, Ltd. Azidohalogenobenzyl derivatives, sugar compounds and protection of hydroxy groups
DE69722178T2 (de) 1996-11-22 2003-11-27 Toray Industries, Inc. Therapeutischer wirkstoff fĂŒr augenerkrankungen
EP0948538B1 (en) 1996-12-13 2008-06-11 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
BR9606270A (pt) 1996-12-18 1998-09-22 Univ Minas Gerais Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
US6436391B1 (en) 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
US6118776A (en) 1997-02-18 2000-09-12 Vixel Corporation Methods and apparatus for fiber channel interconnection of private loop devices
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
JP2002505574A (ja) 1997-04-30 2002-02-19 ă‚šăƒłă‚ŸăƒłïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ポăƒȘă‚ąăƒ«ă‚­ăƒŹăƒłă‚Șă‚­ă‚·ăƒ‰äżźéŁŸă•ă‚ŒăŸć˜éŽ–ăƒăƒȘペプチド
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
HUP0001153A3 (en) 1997-06-06 2000-12-28 Kyowa Hakko Kogyo Kk Chemically modified polypeptides, process for producing thereof, pharmaceutical compositions comprising these polypeptides and their use
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
JP2001512684A (ja) 1997-08-05 2001-08-28 ă‚«ă‚€ăƒ­ăƒł ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł æ–°èŠăźïœïœ‰ïœƒïœˆïœ‰ïœïœïœïœ“ïœ”ïœïœ’ïœ‰ïœ“éșäŒć­é…ćˆ—ăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”šæ–čæł•
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
DE19735593C2 (de) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie HĂŒllprotein-modifizierter Baculovirus-Vektor fĂŒr die Gentherapie
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
WO1999014318A1 (en) 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
CA2320156A1 (en) 1997-09-26 1999-04-08 Uab Research Foundation Reduced antigenic cells and uses therefor
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
DE19748489A1 (de) 1997-11-03 1999-05-06 Roche Diagnostics Gmbh Polyethylenglykol-derivatisierte BiomolekĂŒle und deren Verwendung in heterogenen Nachweisverfahren
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ZA9811070B (en) 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
JP2001526033A (ja) 1997-12-08 2001-12-18 ă‚žă‚§ăƒăƒłăƒ†ă‚Żăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ăƒ’ăƒˆă‚€ăƒłă‚żăƒŒăƒ•ă‚§ăƒ­ăƒłâˆ’ă‚€ăƒ—ă‚·ăƒ­ăƒłăšă„ă†ïœ‰ćž‹ă‚€ăƒłă‚żăƒŒăƒ•ă‚§ăƒ­ăƒł
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
AU2898299A (en) 1998-03-04 1999-09-20 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
ES2222689T3 (es) 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
KR100264953B1 (ko) 1998-04-03 2001-03-02 박현우 ìžŹìĄ°í•© ëČ í˜ëĄœë°”ìŽëŸŹìŠ€, 읎의 ì œìĄ°ë°©ëȕ 및 읎넌 포핹하는 ëŻžìƒëŹŒ 삎충제
JP4574007B2 (ja) 1998-04-28 2010-11-04 ăƒĄăƒ«ă‚Żăƒ»ă‚»ăƒ­ăƒŒăƒŽăƒ»ă‚œă‚·ă‚šăƒ†ăƒ»ă‚ąăƒŽăƒ‹ăƒ  ポăƒȘă‚ȘăƒŒăƒ«âˆ’ïœ‰ïœ†ïœŽâˆ’ăƒ™ăƒŒă‚żè€‡äœ“
WO1999057291A1 (en) 1998-05-07 1999-11-11 Transkaryotic Therapies, Inc. Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU731758B2 (en) 1998-07-08 2001-04-05 Mitsui Chemicals, Inc. Method for secretory production of human growth hormone
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
DE69914611T2 (de) 1998-08-28 2004-12-23 Gryphon Therapeutics, Inc., South San Francisco Verfahren zur herstellung von polyamidketten von genauer lÀnge und deren konjugate mit proteinen
IL142061A0 (en) 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
MXPA01003790A (es) 1998-10-16 2002-09-18 Biogen Inc Proteinas de fusion beta - interferon y sus usos.
HU229888B1 (en) * 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
AU774156B2 (en) 1998-10-30 2004-06-17 Novozymes A/S Glycosylated proteins having reduced allergenicity
EP1016414B1 (en) * 1998-12-17 2004-09-08 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
JP4805432B2 (ja) 1998-12-28 2011-11-02 ăƒ©ăƒłă‚Żă‚»ă‚čăƒ»ăƒ‰ă‚€ăƒăƒ„ăƒ©ăƒłăƒ‰ăƒ»ă‚ČăƒŒă‚šăƒ ăƒ™ăƒŒăƒăƒŒ 朚èłȘæćˆăŻæœšèłȘè€‡ćˆæă‚’èŁœé€ ă™ă‚‹éš›ă«äœżç”šă•ă‚Œă‚‹æŽ„ç€ć‰€æ··ć…„ç”šè–Źć‰€
US6350589B1 (en) 1998-12-31 2002-02-26 Viragen, Inc. Compositions of highly-purified natural mixtures of type I interferon derived from leukocytes and methods
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6994986B2 (en) 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
AU4325900A (en) 1999-03-17 2000-10-04 Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
KR100619611B1 (ko) 1999-04-16 2006-09-01 더랔유엠. ë§ˆì‰Ź 띌읎슀 유니ëČ„ì‹œí‹° 작용화 폮멬(프로필렌 푞마레읎튞) 및 폮멬(í”„ëĄœí•„ë Œí‘žë§ˆë ˆìŽíŠž-윔-에틞렌 êž€ëŠŹìœœ
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
CN1361793A (zh) 1999-05-19 2002-07-31 ćˆ©æ€èż›èŻć“ć…Źćž ćčČ扰玠α蛋癜䜜äžșFcèžćˆè›‹ç™œçš„èĄšèŸŸć’ŒèżèŸ“
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-ÎČ variants and conjugates
US6270756B1 (en) 1999-08-30 2001-08-07 Rx/Ibr Corporation Weight loss induced by alpha interferon and gamma interferon
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
DE60041715D1 (de) 1999-12-22 2009-04-16 Nektar Therapeutics Al Corp Verfahren zur herstellung von 1-benzotriazolcarbonatestern von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
CN1452658A (zh) 2000-03-16 2003-10-29 ć±±ćĄ”ç”Ÿç‰©æŠ€æœŻè‚Ąä»œæœ‰é™ć…Źćž ç”±é—äŒ ć·„çš‹é…”æŻç”Ÿäș§äșșćčČ扰玠α的æ–čæł•
EP1525889A1 (en) * 2000-05-15 2005-04-27 F. Hoffmann-La Roche Ag Liquid pharmaceutical composition containing an erythropoietin derivative
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
JP2002030098A (ja) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd ăƒă‚­ăƒ„ăƒ­ă‚Šă‚Łăƒ«ă‚čたç™șèŠœă‚Šă‚€ăƒ«ă‚čă‹ă‚‰ă‚Šă‚€ăƒ«ă‚čă‚šăƒłăƒ™ăƒ­ăƒŒăƒ—ă‚’ć›žćŽă™ă‚‹æ–čæł•
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
KR100401296B1 (ko) 2000-12-27 2003-10-11 드늌바읎였젠 ìŁŒì‹íšŒì‚Ź ìˆ˜ì‹ëŹŒì§ˆì— 의핎 수식된 닚백질 ëł€ìŽìČŽ 및 읎êČƒì˜ ì œìĄ°ë°©ëȕ
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2002059293A2 (en) 2001-01-25 2002-08-01 Forster Anthony C Process and compositions for peptide, protein and peptidomimetic synthesis
DK2322631T3 (en) 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
US6566132B1 (en) 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
US7232563B2 (en) 2001-08-12 2007-06-19 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
PL369066A1 (en) * 2001-09-04 2005-04-18 Merck Patent Gmbh Modified human growth hormone
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
JP4758608B2 (ja) 2001-11-07 2011-08-31 ăƒă‚Żă‚żăƒŒ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łăƒƒă‚Żă‚č ćˆ†æžăƒăƒȘăƒžăƒŒăŠă‚ˆăłăă‚Œă‚‰ăźç”ćˆäœ“
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
ATE469135T1 (de) 2002-05-30 2010-06-15 Scripps Research Inst Kupferkatalysierte ligierung von aziden und acetylenen
AU2003253781A1 (en) 2002-07-03 2004-01-23 University Of Central Florida Expression of human interferon in transgenic chloroplasts
AU2003270341A1 (en) 2002-09-05 2004-03-29 The General Hospital Corporation Modified asialo-interferons and uses thereof
CA2500653A1 (en) 2002-10-16 2004-04-29 The Scripps Research Institute Glycoprotein synthesis
CA2502029C (en) 2002-10-16 2014-06-10 The Scripps Research Institute Site specific incorporation of keto amino acids into proteins
DE60307881T2 (de) 2002-11-15 2007-03-08 F. Hoffmann-La Roche Ag Positionelle isomeren von pegyliertem interferon alpha 2a
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
KR20050088134A (ko) 2002-12-22 2005-09-01 더 ìŠ€íŹëŠœìŠ€ ëŠŹì„œìč˜ ìžìŠ€í‹°íŠœíŠž 닚백질 얎레읎
MXPA05011127A (es) 2003-04-17 2006-03-10 Scripps Research Inst Expansion del codigo genetico eucariontico.
JP5275566B2 (ja) 2003-06-18 2013-08-28 ザ ă‚čクăƒȘプă‚č ăƒȘă‚”ăƒŒăƒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒăƒ„ăƒŒăƒˆ ććżœæ€§éžć€©ç„¶ă‚ąăƒŸăƒŽé…žéșäŒă‚łăƒŒăƒ‰ä»˜ćŠ 
US20060160175A1 (en) 2003-07-07 2006-07-20 The Scripps Research Institute Compositions of orthogonal leucyl-trna and aminoacyl-trna synthetase pairs and uses thereof
EP1658366A4 (en) 2003-07-07 2006-08-09 Scripps Research Inst COMPOSITIONS OF ORTHOGONAL GLUTAMYL-TRNA AND AMINOACYL-TRNA-SYNTHETASEPAARES AND THEIR USES
AU2004267359B2 (en) 2003-07-07 2010-09-09 The Scripps Research Institute Compositions of orthogonal lysyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof
EP2322569B1 (en) 2003-10-09 2020-08-26 Ambrx, Inc. Polymer derivatives for the selective modification of proteins
WO2005074546A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
US20060040076A1 (en) * 2004-08-18 2006-02-23 Franzyshen Stephen K Formable film for cold-form, blister-type pharmaceutical packaging
KR20070090023A (ko) * 2004-12-22 2007-09-04 ì•”ëžŒëŁ©ìŠ€, ìžìœ”íŹë ˆìŽí‹°ë“œ 변형 읞간 성임 혞넎ëȘŹ
EP3103880A1 (en) * 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses

Also Published As

Publication number Publication date
WO2005074650A2 (en) 2005-08-18
WO2005074546A2 (en) 2005-08-18
US8778880B2 (en) 2014-07-15
AU2005211385B2 (en) 2008-12-11
EP1718339A4 (en) 2008-08-13
KR20060130182A (ko) 2006-12-18
NZ548256A (en) 2010-02-26
US20080114154A1 (en) 2008-05-15
KR20070007086A (ko) 2007-01-12
EP1718664A2 (en) 2006-11-08
IL176596A0 (en) 2008-04-13
JP2007519422A (ja) 2007-07-19
US20050220762A1 (en) 2005-10-06
US20140296145A1 (en) 2014-10-02
US8906676B2 (en) 2014-12-09
US20080103294A1 (en) 2008-05-01
NZ586034A (en) 2011-10-28
US20120142896A1 (en) 2012-06-07
CN103755800B (zh) 2016-02-24
AU2005211362A1 (en) 2005-08-18
US8097702B2 (en) 2012-01-17
JP2007519420A (ja) 2007-07-19
EP1718339A2 (en) 2006-11-08
MXPA06008507A (es) 2008-02-13
US20080103293A1 (en) 2008-05-01
KR101207123B1 (ko) 2012-12-04
US20050170404A1 (en) 2005-08-04
GB2429207A8 (en) 2007-03-05
IL176595A (en) 2014-12-31
US20080097083A1 (en) 2008-04-24
BRPI0507118A (pt) 2007-06-19
EP1740608A4 (en) 2008-09-03
GB2429207A9 (en) 2007-03-05
US20080146781A1 (en) 2008-06-19
WO2005074524A3 (en) 2007-03-29
JP2007520223A (ja) 2007-07-26
HK1099776A1 (en) 2007-08-24
NZ548255A (en) 2010-10-29
CN103755800A (zh) 2014-04-30
MXPA06008496A (es) 2007-01-30
KR20060130181A (ko) 2006-12-18
AU2009200832A1 (en) 2009-03-19
US8119603B2 (en) 2012-02-21
IL176595A0 (en) 2008-04-13
MXPA06008506A (es) 2007-01-30
EP1740608B1 (en) 2012-02-22
BRPI0507159A (pt) 2007-06-26
AU2005211385A1 (en) 2005-08-18
CA2553034A1 (en) 2005-08-18
GB0617302D0 (en) 2006-10-18
JP4889505B2 (ja) 2012-03-07
EP1740608A2 (en) 2007-01-10
CA2553040A1 (en) 2005-08-18
AU2011202106B2 (en) 2012-09-13
JP4896745B2 (ja) 2012-03-14
GB0617303D0 (en) 2006-10-18
WO2005074524A2 (en) 2005-08-18
EP2327724A3 (en) 2011-07-27
AU2005209926B2 (en) 2007-09-06
ATE546463T1 (de) 2012-03-15
WO2005074650A3 (en) 2006-09-28
NZ548257A (en) 2011-02-25
AU2005211362B2 (en) 2008-03-13
GB2426762A (en) 2006-12-06
US20080161539A1 (en) 2008-07-03
CA2553035A1 (en) 2005-08-18
AU2005209926A1 (en) 2005-08-18
GB2426521A (en) 2006-11-29
BRPI0507169A (pt) 2007-06-26
US20080207877A1 (en) 2008-08-28
US8232371B2 (en) 2012-07-31
EP2327724A2 (en) 2011-06-01
US20080108791A1 (en) 2008-05-08
AU2009200832B2 (en) 2012-05-10
WO2005074546A3 (en) 2007-01-04
GB0617304D0 (en) 2006-10-25
GB2429207A (en) 2007-02-21
US20080108797A1 (en) 2008-05-08
SG135176A1 (en) 2007-09-28
US8907064B2 (en) 2014-12-09
US9260472B2 (en) 2016-02-16
EP1718664A4 (en) 2008-08-13
AU2011202106A1 (en) 2011-05-26
US20080300163A1 (en) 2008-12-04
US20080114155A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
GB0617302D0 (en) Modified human four helical bundle polypeptides and their uses
GB2436266A (en) Modified human growth hormone
PL2272873T3 (pl) PrzeciwciaƂa przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
IL181083A0 (en) Synthetic hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
IL207422A0 (en) Improved recombinant human interferon-beta-ib polypeptides
EG24035A (en) Gantry with auto-adjusting prestressing
AU2003226899A8 (en) Human diabetes-mediating proteins
ZA200606224B (en) Modified human growth hormone polypeptides and their uses
ZA200704926B (en) Modified human growth hormone
HUP0402334A3 (en) Modified human growth hormone
AU2003252075A8 (en) Human immunosuppressive protein
IL178389A0 (en) Human glycoprotein hormone superagonists and uses thereof
IL173194A0 (en) Human growth hormone in parkinson-plus syndromes
AU2003271452A8 (en) Modified glp-1 peptides with increased biological potency
HK1098485A (en) Modified human four helical bundle polypeptides and their uses
TW557712U (en) The needle for tattoo the eyebrows or bodies
GB0206589D0 (en) Head lice treatment material
HK1113591A (en) Modified human growth hormone
GB0218439D0 (en) Growth promotoin in animals using sub-perception
GB0325493D0 (en) Electronically supported human moderation and marking process
GB0404199D0 (en) Therapeutic and diagnostic peptides 2